desipramine hydrochloride

Phase 2Small molecule

Novartis

desipramine hydrochloride is one of 65 small molecule programs targeting Back pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Back PainActive, not recruiting

Multiple MyelomaActive, not recruiting

Back PainPhase 2

Active, not recruiting

Multiple MyelomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 4

Adriamycin

GGynecologic Oncology Group

Preclinical

9 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Merck & Co.

Preclinical

—8

desipramine hydrochloride

Novartis

Phase 2

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Back pain1 trial

Efficacy of Antidepressants in Chronic Back Pain

Completed·VVA Office of Research and Development·Phase 2·NCT00964886·142 enrolled

Multiple Myeloma1 trial

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Terminated·—·N/A·NCT01899326·10 enrolled

Unspecified2 trials

To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets

Completed· Novartis logo

Novartis·Phase 1·NCT00913822·36 enrolled

To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets

Completed· Novartis logo

Novartis·Phase 1·NCT00913237·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for desipramine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — desipramine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for desipramine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

desipramine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Back pain1 trial

Multiple Myeloma1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News